Clinical Trial

tDCS Plus Varenicline for Smoking Cessation

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to determine if active transcranial direct current stimulation (tDCS) plus varenicline is an effective, safe and accessible treatment option for smoking cessation. The main questions this trial aims to answer are: 1. Does active tDCS plus varenicline improve short-term and long-term smoking abstinence rates compared to sham tDCS plus varenicline? 2. Are the safety profiles between active tDCS plus varenicline and sham tDCS plus varenicline different? The tDCS treatment schedule includes 10 daily sessions for the first 2 weeks (M to F), followed by 5 single bi-weekly booster sessions for the remainder of the treatment period. Participants will come in-person for two follow-up sessions to assess smoking behaviour at 6- and 12-months post-treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-22; most recent amendment 2025-08-07.
Status change: Not Yet Recruiting → Recruiting 2025-08-07
Trial Details
NCT Number NCT06798324
Lead Sponsor Centre for Addiction and Mental Health
Collaborators: Canadian Institutes of Health Research (CIHR)
Conditions Nicotine Dependence, Tobacco Smoking, Smoking Cessation, Nicotine Use Disorder, Tobacco Use Disorder, Substance Use Disorders
Enrollment 160 participants
Start Date 2025-03-10
Primary Completion 2028-01-20 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-12